Drug Discovery & DDS– category –
-
Drug Discovery & DDS Weekly Report June 28, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report June 28, 2026 (PDF) — Download Weekly Report June 28, 2026 (PDF) — DownloadDownload 🎙 Podcast June 28, 2026 (... -
Ionis Forges $30M Ex-US Rare Disease Pact with Recordati, Accelerating Global ASO Reach
Fierce Biotech USA Overview Ionis Pharmaceuticals has secured a $30 million upfront payment from Recordati, granting the Italian firm exclusive ex-US development and commercialization rights for specific rare disease therapies. This stra... -
Boehringer Ingelheim Fuels Immunai’s AI with $15M to Unlock T-Cell Secrets for Cancer, Autoimmune Drug Discovery
Fierce Biotech USA Overview Boehringer Ingelheim (BI) has invested $15 million in Immunai's advanced AI platform, initiating a collaborative research agreement. This partnership aims to accelerate drug discovery for cancer and autoimmune... -
Otsuka’s ADHD Therapy Poised for FDA Approval Following Successful Phase 3b Clinical Trial
Fierce Biotech USA Overview Otsuka Pharmaceutical announced positive outcomes from its Phase 3b clinical trial for an Attention-Deficit/Hyperactivity Disorder (ADHD) treatment, marking a crucial step ahead of its U.S. Food and Drug Admin... -
Elixirgen Therapeutics and Nippon Shinyaku Forge Alliance for Next-Gen DMD Therapy EXG-7001
GlobeNewswire Japan Overview Elixirgen Therapeutics and Nippon Shinyaku have signed an option agreement for the development and commercialization of EXG-7001, a promising therapeutic candidate for Duchenne Muscular Dystrophy (DMD). This ... -
Bayer and Iambic Therapeutics Partner to Drive Small Molecule Drug Discovery with AI Platform
BioSpace USA Overview Bayer has announced a strategic collaboration with Iambic Therapeutics, leveraging Iambic's advanced AI platforms, Enchant and NeuralPLexer, for small molecule drug discovery. This partnership aims to significantly ... -
Biotech CEOs Anticipate Funding Rebound by Late 2026, Pin Hopes on FDA for Streamlined Drug Development
Endpoints News USA Overview A recent Endpoints 100 survey reveals 62% of biotech CEOs anticipate a significant improvement in the funding environment by late 2026, driven by a recovering IPO market and increased M&A activity. These l... -
Antares and Novartis Forge $1.9B Deal to Tackle ‘Undruggable’ Cancer Targets with Small Molecules
Business Wire USA Overview Antares Therapeutics and Novartis have announced a strategic collaboration to discover, develop, and commercialize first-in-class small molecule therapies for previously 'undruggable' cancer targets. The agreem... -
Biogen Pivots Post-Apellis Acquisition: Halts Most R&D, Concentrates on Commercial Assets
Endpoints News USA Overview Biogen has confirmed it will suspend or terminate "most" of Apellis Pharmaceuticals' research programs and lay off some employees following its $5.6 billion acquisition. This strategic pivot is part of integra... -
RQ Bio Secures $115M to Fast-Track Long-Acting Antibody RQB01, Revolutionizing Flu Prevention for Vulnerable Patients
GlobeNewswire UK Overview RQ Bio has successfully closed a $115 million (approximately £85.5 million) Series A funding round, led by Frazier Life Sciences, to accelerate the clinical development of RQB01. This long-acting antibody progra...
